ER

Mahoney becomes CEO and president of Boston Scientific

Friday, November 2, 2012 11:52 AM

Boston Scientific, a global developer, manufacturer and marketer of medical devices, has named Michael F. Mahoney its new CEO and president. Mahoney succeeds interim CEO William H. (Hank) Kucheman. Mahoney has also been appointed to the Boston Scientific board of directors. 

More... »

Vertex, GSK partner on phase II all-oral study of VX-135, GSK2336805 for Hep C

Friday, November 2, 2012 11:23 AM

Vertex Pharmaceuticals, a global biotechnology company based in Cambridge, Mass., has entered into a non-exclusive agreement with GlaxoSmithKline (GSK) to conduct a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex's nucleotide analogue HCV polymerase inhibitor VX-135 and GSK's NS5A inhibitor GSK2336805.

More... »

Ensemble, Boehringer Ingelheim collaborate on macrocycle drug candidates

Friday, November 2, 2012 10:56 AM

Ensemble Therapeutics of Cambridge, Mass., has initiated a research collaboration with Germany-based Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called macrocycles, against several high-value pharmaceutical targets specified by Boehringer Ingelheim.

More... »

FDA grants Bayer’s Stivarga NDA priority review

Thursday, November 1, 2012 11:49 AM

Bayer HealthCare and Onyx Pharmaceuticals, a biopharmaceutical company based in South San Francisco, announced today that the FDA has granted priority review to the New Drug Application (NDA) for Stivarga (regorafenib) tablets.

More... »

Keryx initiates phase II study of Zerenex in chronic kidney disease

Thursday, November 1, 2012 10:25 AM

Keryx Biopharmaceuticals, a biopharmaceutical company based in New York, N.Y., has initiated a phase II study of Zerenex (ferric citrate), the company's ferric iron-based phosphate binder drug candidate, in managing serum phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease (NDD-CKD).

More... »

Charles River to acquire Vital River, expands research models business

Thursday, November 1, 2012 09:28 AM

Charles River Laboratories International, a global provider of research products and services, has entered into an agreement to acquire 75% ownership of Vital River, a Chinese commercial provider of research models and related services.

More... »

Thesan Pharmaceuticals closes $16M Series A funding

Wednesday, October 31, 2012 02:04 PM

Thesan Pharmaceuticals, a newly-formed biotech focused on dermatological conditions, has closed a $16M Series A financing, co-led by Novo Ventures and Novartis Venture Funds. 

More... »

Theratechnologies revises business plan, cuts 15 employees

Wednesday, October 31, 2012 10:39 AM

Theratechnologies, a Canadian specialty pharmaceutical company focused on therapeutic peptide products, has revised its business plan which will focus on revenue growth from tesamorelin in the short term and expenditure control.

More... »

Apredica, Pfizer ink collaborative research agreement

Wednesday, October 31, 2012 09:43 AM

Apredica, a subsidiary of Cyprotex, a preclinical ADME-Tox services company, has signed a collaborative research agreement with Pfizer, a global research-based pharmaceutical company.

More... »

Bayer to acquire Schiff Nutrition International for $ 1.2B

Wednesday, October 31, 2012 09:15 AM

Bayer HealthCare has signed a merger agreement to acquire Schiff Nutrition International, a company offering vitamins and nutritional supplements in the U.S. and other countries, for $1.2 billion, representing a value of $34 per share in cash.

More... »